Pharmacokinetic Evaluation of LY03010 and Its Relative Bioavailability Compared to Paliperidone Palmitate in Schizophrenia Patients

The primary objective of this study is to evaluate the **pharmacokinetic** profiles of LY03010 and assess the relative bioavailability at steady-state of LY03010 compared to XEPLION® in patients with **schizophrenia**. Understanding the pharmacokinetic properties and bioavailability of LY03010 is clinically relevant as it may inform dosing strategies and therapeutic efficacy in managing schizophrenia, a chronic mental health disorder characterized by disturbances in thought processes, perceptions, and emotional responsiveness.

The clinical trial involves a total of **158 participants** diagnosed with **schizophrenia**. The study population includes both male and female subjects, with an age range spanning from 18 to 64 years. Participants were selected to represent a vulnerable population, although specific inclusion or exclusion criteria were not provided by the sponsor. The trial does not specify any particular lifestyle considerations such as diet, physical activity, or habits. The selection process aimed to ensure a representative sample of individuals affected by the condition under investigation.

The clinical trial is designed as a **randomized**, multiple-dose, open-label, parallel-group study to evaluate the pharmacokinetic profiles and relative bioavailability of LY03010 compared to XEPLION® in patients diagnosed with **schizophrenia**. The trial is categorized as a Phase 2 study and is expected to commence recruitment on September 1, 2024, with an estimated completion date of December 31, 2025. The study will involve a series of structured visits, beginning with an inclusion visit where participants will be screened for eligibility based on predefined criteria. This initial visit will ensure that only suitable candidates are enrolled in the trial.

Following the inclusion visit, participants will undergo multiple study visits at regular intervals to monitor their response to the treatment and to collect necessary pharmacokinetic data. These visits are crucial for assessing the safety and efficacy of the investigational product. The trial will conclude with an end-of-study visit, where final assessments will be conducted to evaluate the overall outcomes of the treatment regimen. The expected duration of participant involvement will span the entire trial period, from the initial screening to the end-of-study visit, unless specific conditions necessitate early termination. Such conditions may include adverse reactions, non-compliance with study protocols, or withdrawal of consent by the participant. The trial's design and procedures are meticulously structured to ensure the collection of reliable and valid data, contributing to the understanding of the investigational product's pharmacokinetic properties in the target population.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a paediatric formulation or if it has orphan drug status. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In addition to the experimental medication, the study may include the use of **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatment. However, the data does not provide explicit details about these treatments. Information regarding the administration, dosing schedules, and participant compliance monitoring for these non-experimental treatments is also not available in the provided data.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 2 study, indicating its focus on evaluating the efficacy and side effects of the intervention. The estimated recruitment start date is September 1, 2024, with an anticipated end date of December 31, 2025. The trial will employ scientifically validated methods to measure and analyze efficacy parameters, although specific endpoints and measurement tools are not detailed in the available data. The study will adhere to rigorous standards to ensure the reliability and validity of the efficacy assessments conducted throughout the trial duration.